GlassScriptPhysician profile
Christie E Choi
NPI 1629207550
$10,905.65
in general payments reported to CMS, 2019-2025
45 companies · $1,548 in 2025
The $1,548 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,929 · 2020: $855 · 2021: $1,664 · 2022: $1,242 · 2023: $1,444 · 2024: $2,224 · 2025: $1,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,189 · Education: $26.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,189.15 |
| Education | $26.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,513.48 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,369.58 | 2019-2025 | Entyvio |
| Pfizer INC. | $1,078.56 | 2019-2025 | |
| Janssen Biotech, INC. | $683.36 | 2019-2025 | Stelara, Tremfya, Simponi |
| Micro-Tech Endoscopy USA, INC. | $517.77 | 2019 | |
| Celgene Corporation | $441.05 | 2021-2024 | Zeposia |
| Daiichi Sankyo INC. | $383.34 | 2019-2024 | Injectafer |
| Qol Medical, LLC | $270.86 | 2019-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $208.46 | 2019-2024 | Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.95 | 2019-2024 | Trulance, Xifaxan |
| Phathom Pharmaceuticals, INC. | $116.85 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $110.55 | 2024-2025 | Omvoh |
| Janssen Scientific Affairs, LLC | $110.50 | 2021 | |
| Romark Laboratories, Lc | $97.66 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $84.89 | 2022-2025 | Dupixent |
Show all 44 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$43,328.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christie Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.